KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.3 billion.

  • BeOne Medicines' Net Cash Flow rose 185766.28% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 44460.19%. This contributed to the annual value of -$495.5 million for FY2024, which is 2723.16% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Net Cash Flow is $1.3 billion, which was up 185766.28% from $232.0 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Net Cash Flow ranged from a high of $3.4 billion in Q4 2021 and a low of -$398.5 million during Q3 2021
  • For the 5-year period, BeOne Medicines' Net Cash Flow averaged around $168.6 million, with its median value being -$60.0 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 372163.87% in 2021, then tumbled by 81508.94% in 2023.
  • BeOne Medicines' Net Cash Flow (Quarter) stood at $3.4 billion in 2021, then crashed by 111.51% to -$390.0 million in 2022, then skyrocketed by 116.11% to $62.8 million in 2023, then tumbled by 136.56% to -$23.0 million in 2024, then skyrocketed by 5823.4% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $232.0 million for Q2 2025, and -$111.6 million during Q1 2025.